Role of ADAM 17 in epithelial dysregulation in COPD - Role of ADAM 17 in epithelial dysregulation in COPD

niversitair Medisch Centrum Groningen0 个研究点目标入组 50 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Age between 40 and 75 years
•A medical indication to undergo a bronchoscopy;Inclusion criteria for healthy smokers:
•Individuals who currently smoke >= 10 cigarettes/day and > 10 packyears.
•Documented FEV1 > 80% predicted, FEV1/FVC > 70%.;Inclusion criteria for healthy never smokers:
•Individuals, who have not smoked during the at least last year, have never
•smoked for as long as a year (i.e. at least one cigarette per day or one cigar per week, AND have < 0.5 packyear.
•Documented FEV1 > 80% predicted, FEV1/FVC > 70%.;Inclusion criteria for healthy ex-smokers:
•Individuals, who have not smoked during the last year, but who do have a smoking history with at least 10 packyears.
•Documented FEV1 > 80% predicted, FEV1/FVC > 70%.;inclusion criteria for smokers with COPD:
•> 10 packyears and current smoking.
•FEV1 < 80% predicted and FEV1/FVC < 70% of predicted.;inclusion criteria for ex- smokers with COPD:
•Age between 40-75 years.
•> 10 packyears. No smoking during the last year and a smoking history with at least 10 packyears.
•FEV1 < 80% predicted and FEV1/FVC < 70% of predicted.
•Referred by own physician for a bronchoscopy

•Use of an anticoagulans (i.e. vitamin K antagonists) or the use of LMWh (low molecular weight heparin).

发起方